Compare CPRI & PHVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CPRI | PHVS |
|---|---|---|
| Founded | 1981 | 2015 |
| Country | United Kingdom | Switzerland |
| Employees | N/A | N/A |
| Industry | Apparel | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.4B | 2.4B |
| IPO Year | 2011 | 2020 |
| Metric | CPRI | PHVS |
|---|---|---|
| Price | $16.67 | $34.26 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 13 | 11 |
| Target Price | $26.62 | ★ $41.82 |
| AVG Volume (30 Days) | ★ 2.5M | 556.3K |
| Earning Date | 05-27-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 111.40 | N/A |
| EPS | ★ 1.14 | N/A |
| Revenue | ★ $3,474,000,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $1.81 | N/A |
| P/E Ratio | $15.32 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $16.72 | $19.12 |
| 52 Week High | $28.27 | $36.60 |
| Indicator | CPRI | PHVS |
|---|---|---|
| Relative Strength Index (RSI) | 33.66 | 55.66 |
| Support Level | N/A | $24.73 |
| Resistance Level | $22.08 | N/A |
| Average True Range (ATR) | 0.82 | 1.59 |
| MACD | -0.26 | -0.04 |
| Stochastic Oscillator | 0.18 | 36.21 |
Capri Holdings is a marketer, distributor, and retailer of upscale accessories and apparel in the Americas, Europe, and Asia. Michael Kors, Capri's original and largest brand by sales, offers handbags, footwear, and apparel through more than 700 company-owned stores, wholesale, and e-commerce. Jimmy Choo (acquired in 2017) is best known for women's luxury footwear. Its products are sold in more than 200 company-operated stores. John Idol has served as Capri's CEO since 2003.
Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks. The company is also running open-label extension studies in both on-demand (RAPIDe-2) and prophylactic (CHAPTER-4) settings to collect long-term safety and efficacy data in HAE patients.